Abstract

Autoantibodies to various cellular constituents are detected in the sera of patients with idiopathic inflammatory myopathy (IIM). These autoantibodies are closely associated with characteristic clinical manifestations of the diseases. Therefore, autoantibodies give us much information in clinical diagnosis, classification, prediction of prognosis and choice of treatment in patients with IIM. During the last decade, novel myositis-specific autoantibodies have been identified, such as anti-CADM-140, anti-p155, anti-NXP-2, anti-SAE and anti-200/100, all of which except anti-200/100 are dermatomyositis-specific autoantibodies. The anti-CADM-140 antibody is associated with clinically amyopathic dermatomyositis and acute progressive interstitial pneumonia, anti-p155 is identified in malignancy-associated myositis and anti-200/100 is associated with necrotizing myositis. These new autoantibodies are extremely important because it had been thought that autoantibodies were negative in such subgroups. Target autoan...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call